178 related articles for article (PubMed ID: 31526159)
21. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
[TBL] [Abstract][Full Text] [Related]
22. Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development.
Ollier R; Wassmann P; Monney T; Ries Fecourt C; Gn S; C A V; Ayoub D; Stutz C; Gudi GS; Blein S
MAbs; 2019; 11(8):1464-1478. PubMed ID: 31462177
[TBL] [Abstract][Full Text] [Related]
23. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
[TBL] [Abstract][Full Text] [Related]
24. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
[TBL] [Abstract][Full Text] [Related]
25. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
26. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
27. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
28. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors.
Radaev S; Sun PD
J Biol Chem; 2001 May; 276(19):16478-83. PubMed ID: 11297533
[TBL] [Abstract][Full Text] [Related]
29. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
Ha S; Ou Y; Vlasak J; Li Y; Wang S; Vo K; Du Y; Mach A; Fang Y; Zhang N
Glycobiology; 2011 Aug; 21(8):1087-96. PubMed ID: 21470983
[TBL] [Abstract][Full Text] [Related]
30. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
31. Effect of the ADCC-Modulating Mutations and the Selection of Human IgG Isotypes on Physicochemical Properties of Fc.
Wu HH; Crames M; Wei Y; Liu D; Gueneva-Boucheva K; Son I; Frego L; Han F; Kroe-Barrett R; Nixon A; Marlow M
J Pharm Sci; 2022 Sep; 111(9):2411-2421. PubMed ID: 35760121
[TBL] [Abstract][Full Text] [Related]
32. Engineered IgG1-Fc--one fragment to bind them all.
Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
[TBL] [Abstract][Full Text] [Related]
33. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
34. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
Branstetter E; Duff RJ; Kuhns S; Padaki R
FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
[TBL] [Abstract][Full Text] [Related]
35. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J
Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
Schaefer W; Regula JT; Bähner M; Schanzer J; Croasdale R; Dürr H; Gassner C; Georges G; Kettenberger H; Imhof-Jung S; Schwaiger M; Stubenrauch KG; Sustmann C; Thomas M; Scheuer W; Klein C
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11187-92. PubMed ID: 21690412
[TBL] [Abstract][Full Text] [Related]
37. Improving target cell specificity using a novel monovalent bispecific IgG design.
Mazor Y; Oganesyan V; Yang C; Hansen A; Wang J; Liu H; Sachsenmeier K; Carlson M; Gadre DV; Borrok MJ; Yu XQ; Dall'Acqua W; Wu H; Chowdhury PS
MAbs; 2015; 7(2):377-89. PubMed ID: 25621507
[TBL] [Abstract][Full Text] [Related]
38. When binding is enough: nonactivating antibody formats.
Labrijn AF; Aalberse RC; Schuurman J
Curr Opin Immunol; 2008 Aug; 20(4):479-85. PubMed ID: 18577454
[TBL] [Abstract][Full Text] [Related]
39. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
40. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.
Romain G; Senyukov V; Rey-Villamizar N; Merouane A; Kelton W; Liadi I; Mahendra A; Charab W; Georgiou G; Roysam B; Lee DA; Varadarajan N
Blood; 2014 Nov; 124(22):3241-9. PubMed ID: 25232058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
